Resverlogix sees early success and expedites Phase 2 plans
TSX Exchange Symbol: RVX
CALGARY, Jan. 14 /CNW/ - Resverlogix is pleased to announce preliminary
data from the RVX-208 Phase 1 safety and pharmacokinetics study. Forty healthy
volunteers have so far been treated of which sixteen have received multiple
doses. As anticipated from the extensive Investigational New Drug toxicology
studies no safety and tolerance problems have been encountered at any of the
given doses. "The pharmacokinetics (drugability) of RVX-208 has exceeded our
highest expectations," stated Donald J. McCaffrey, President & CEO of
Resverlogix. "We are very confident about the further progress of the RVX-208
clinical program and the eventual successful completion of Phase 1. The
current phase 1 study includes a total of 80 healthy men and women in a study
comprising three arms: single dose escalation, food vs. fasted effect on
pharmacokinetics and 3 cohorts with 7-day multiple dosing."
McCaffrey noted, "Due to the successful early trending of our Phase 1
program we have decided that upon official completion of the trial, FDA
discussions and approval, we will be expediting our plans for a Phase 2 trial.
This could shorten the time to reach our Phase 2 trial by several months. In
addition, follow on studies in cardiovascular disease patients are being
discussed with potential collaborators. The medical community recognizes that
permanently increasing ApoA-I production, plasma HDL and promoting reverse
cholesterol transport by a small molecule has unprecedented potential to cure
About Cardiovascular Disease (CVD)
CVD can be generally defined as any abnormal condition characterized by
dysfunction of the heart and blood vessels. CVD includes atherosclerosis
(especially coronary heart disease which can lead to heart attacks),
cerebrovascular disease (stroke), and hypertension (high blood pressure). The
underlying cause of most CVD is a gradual clogging of the arteries
(atherosclerosis) that supply blood to the heart, brain and other vital
The American Heart Association estimates that almost 80 million American
Adults have one or more types of cardiovascular disease. CVD remains the
number one killer of developed nations. Nearly 2400 Americans die each day
from cardiovascular disease - that is 1 person will die every 36 seconds.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's and other
vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as cancer and
fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email:
Sarah@resverlogix.com; Website: www.resverlogix.com